

Position Paper: Optical Hazard of Solar Radiation on the Dilated Eye

Introduction

Solar radiation poses a significant yet often overlooked risk to ocular health, particularly in eyes that have been pharmacologically dilated. Dilation removes the eye's natural defense—pupillary constriction—thereby increasing retinal exposure to harmful ultraviolet (UV) and high-energy visible (HEV) light. As eye care providers, it is essential to understand the science behind phototoxic injury, recognize the increased vulnerability of the dilated eye, and advocate for preventive measures. Ensuring that pupil dilation is conducted under medical supervision is also crucial in minimizing avoidable retinal damage.

Understanding Retinal Phototoxicity

Retinal phototoxicity occurs through three primary mechanisms: photochemical, photothermal, and photomechanical injury (Glickman, 2002). Each mechanism is influenced by the wavelength, intensity, and especially the duration of light exposure. Photochemical damage arises from prolonged exposure to low-intensity UV or blue light, resulting in oxidative stress and retinal injury without a significant rise in temperature. Photothermal damage occurs when light energy is absorbed faster than it can dissipate, raising tissue temperature and causing protein denaturation. Photomechanical injury results from extremely short, high-intensity light pulses that generate shockwaves and physically disrupt retinal tissue. Among these, photochemical injury is the most clinically relevant in daily life—especially when pharmacologic dilation allows greater quantities of UV and HEV light to enter the eye and reach the retina.

Mydriatics and Increased Risk

Mydriatic agents vary in onset and duration depending on their pharmacologic class. Anticholinergic drugs such as atropine, homatropine, cyclopentolate, and tropicamide induce both mydriasis and cycloplegia by inhibiting the sphincter pupillae and ciliary muscles. Atropine has the longest duration, lasting up to 7–12 days, while shorter-acting agents like cyclopentolate and tropicamide are preferred for routine eye exams. Sympathomimetic agents like phenylephrine cause mydriasis without cycloplegia and have a shorter duration of action, typically 4–6 hours. Regardless of the specific agent, dilation increases the retina's exposure to potentially damaging solar radiation. This risk is particularly concerning when patients remain outdoors without protective eyewear during the hours following dilation.

Clinical Evidence Supporting Risk

The link between pharmacologic mydriasis and retinal phototoxicity is supported by clinical evidence. A recent case report by Cheon (2024) described a patient who developed bilateral solar retinopathy after prolonged sun exposure while taking antidepressants known to induce mydriasis. The patient presented with bilateral blurred vision and characteristic foveal lesions. Optical coherence tomography confirmed retinal changes consistent with solar retinopathy. The condition was resolved following sun protection measures and adjustment of the antidepressant regimen. This case underscores that pupil dilation—whether induced by ophthalmic drugs or systemic medications—can significantly increase retinal vulnerability to light-induced injury.

Preventive Measures: Simple but Essential

Despite the increased risk, prevention is simple and highly effective. Patients should be advised to wear sunglasses that block 99–100% of UVA and UVB rays, avoid direct sunlight for several hours after dilation, and use broad-brimmed hats or post-mydriatic protective spectacles when outdoors. Patient education plays a critical role in prevention. Verbal and written instructions regarding post-dilation photosensitivity and the risk of solar exposure can significantly reduce the likelihood of harm. Even brief counseling during the clinical encounter can reinforce protective behaviors.

Medical Oversight of Pupil Dilation

All pharmacologic dilations should be performed by licensed physicians or under their direct supervision. This ensures appropriate patient selection, proper use of pharmacologic agents, and timely identification of risk factors such as pre-existing retinal disease or excessive sun exposure. Medical oversight allows for thorough pre- and post-procedure counseling and the prompt management of complications, helping to minimize risk while preserving the diagnostic and therapeutic benefits of dilation.

Conclusion

The optical hazard posed by solar radiation on the pharmacologically dilated eye is both scientifically validated and clinically observed. With proper understanding of the mechanisms of phototoxicity and the documented risks of prolonged light exposure following dilation, it is clear that preventive strategies are necessary. Ensuring physician-led dilation, educating patients, and encouraging protective measures such as UV-blocking eyewear can effectively safeguard vision while maintaining the essential benefits of pupil dilation.

Philippine Academy of Ophthalmology

- Roseny Mae Singson, MD, FPAO, FAPSOPRS, FPSOPRS
- Beltran Alexis Aclan, MD, MHCM
- Sheila Mae Santos-Jimenez, MD
- Maria Victoria Rondaris, MD, MPH

References

- Cheon, E.J. (2024). Solar retinopathy related to antidepressant use in a patient with major depressive disorder: A case report. *Journal of Yeungnam Medical Science*, 41(3), 228–232. <https://doi.org/10.12701/jyms.2024.00213>
- Glickman, R. D. (2002). Phototoxicity to the retina: Mechanisms of damage. *International Journal of Toxicology*, 21(6), 473–490. <https://doi.org/10.1080/10915810290169909>
- American Academy of Ophthalmology. "Solar Retinopathy." Section 12: Retina and Vitreous. Singapore, 2013-2014. 332-334.
- Youssef PN, Sheibani N, Albert DM. Retinal light toxicity. *Eye* (2011);25:1–14. doi:10.1038/eye.2010.149